AstraZeneca’s Farxiga (dapagliflozin) Receives the US FDA’s Approval for the Treatment of Heart Failure
- The US FDA has approved Farxiga to reduce the risk of CV death, hospitalization for heart failure & urgent HF visits in adults with HF
- The approval was based on the P-III trial (DELIVER) evaluating dapagliflozin (administered as qd in addition to background therapy) vs PBO in 6263 randomized patients with HF with LVEF ≥40% with/out T2D. The results showed an early reduction in the primary composite EPs of CV death or worsening HF in patients with HF with HFmrEF or HFpEF
- The results were published in the NEJM. Farxiga was approved in the US for adults with HFrEF & was also approved for T2D, HFrEF, and CKD in 100+ countries globally incl. the US, the EU, China, and Japan
Ref: AstraZeneca | Image: AstraZeneca
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at email@example.com
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.